Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

sacituzumab govitecan

20th May 2025

Plain language summary: EVOKE-01 study comparing sacituzumab govitecan vs docetaxel for lung cancer

16th Sep 2024

Plain language summary of the ASCENT Study: Sacituzumab Govitecan for metastatic triple-negative breast cancer

Sacituzumab govitecan (brand name: TRODELVY®) is a new treatment being studied for people with a type of bladder cancer, called urothelial cancer, that has progressed to a locally advanced or metastatic stage. Locally advanced and metastatic urothelial cancer are usually treated with platinum-based chemotherapy. Metastatic urothelial cancer is also treated with immune checkpoint inhibitors. There are few treatment options for people whose cancer gets worse after receiving these treatments. Sacituzumab govitecan is a suitable treatment option for most people with urothelial cancer because it aims to deliver an anti-cancer drug directly to the cancer in an attempt to limit the potential harmful side effects on healthy cells. This is a summary of a clinical study called TROPHY-U-01, focusing on the first group of participants, referred to as Cohort 1. All participants in Cohort 1 received sacituzumab govitecan
30th Apr 2024

Sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer- a plain language summary of the TROPHY-U-01 study

1st Sep 2021

A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy